Experimental study on the optimization of ANM33 release in foam cells

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Cardiovascular Research

Background:

• MicroRNA-33 (miR-33) plays a key role in atherosclerosis (AS) pathogenesis.
• Targeted delivery of therapeutic agents to specific cells is crucial for effective AS treatment.

Purpose of the Study:

• To investigate the therapeutic potential of hyaluronic acid-poly(lactic-co-glycolic acid) nanobubbles (HA-PANBs) for atherosclerosis gene therapy.
• To evaluate the efficacy of HA-PANBs in delivering anti-miR-33 (ANM33) oligonucleotides specifically to foam cells.

Main Methods:

• Co-cultured cell model of phagocytosis was used to examine intracellular localization and loading optimization of HA-PANBs.
• Therapeutic effects of HA-PANBs were assessed in comparison to non-targeting nanobubbles (NBs) and single-targeted microbubbles.
• RNA silencing mediated by ANM33 delivered via HA-PANBs was evaluated.

Main Results:

• HA-PANBs demonstrated efficient and specific delivery of ANM33 to foam cells via sustained release.
• Optimal dosage identified: 12 µg/mL HA-PANBs per 10^7 cells for 48 hours resulted in higher release rate and drug efficacy.
• HA-PANBs showed superior performance compared to control groups in targeted delivery and therapeutic effect.

Conclusions:

• HA-PANBs represent a novel and effective gene therapy approach for early atherosclerosis management.
• Targeted delivery of ANM33 using HA-PANBs shows promise in preventing AS progression and severity.
• Sustained release and foam cell-specific targeting enhance the clinical value of HA-PANBs for AS treatment.